Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesCytogenetic StudiesCPT cpt-88269-amniotic-fluid-cell-chromosome-analysis-karyotype
    Ask Trek AI about this page

    CPT 88269: Chromosome Analysis of Cultured Amniotic Fluid Cells

    CPT code 88269 describes chromosome analysis performed on cultured amniotic fluid cells examined in situ, with counts from six to 12 colonies and preparation of one banded karyotype; this is a cytogenetic analysis procedure typically performed as a laboratory genetic diagnostic service on amniotic fluid specimens collected in an outpatient or hospital prenatal setting.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 88269 policy alerts

    Get alerted when payer policies referencing 88269 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A pregnant patient at 15–20 weeks gestation undergoes diagnostic amniocentesis after abnormal prenatal screening results (for example, abnormal first- or second‑trimester serum screen, abnormal cell‑free DNA, or ultrasound finding such as increased nuchal translucency or major structural anomaly). Amniotic fluid is collected by an obstetrician or maternal‑fetal medicine specialist and sent to a cytogenetics laboratory. In the lab, a cytogenetics analyst performs in situ chromosome analysis of cultured amniotic fluid cells: colonies are grown on a surface, cells from six to 12 colonies are counted, and a single banded karyotype is prepared and interpreted. The workflow includes specimen accessioning, culture setup, cell harvesting and fixation on slides, banding (typically G‑banding), microscopic analysis, karyotype assembly, interpretation, and generation of a written report. Results guide prenatal counseling regarding chromosomal aneuploidy or structural rearrangements and may prompt additional testing such as microarray or targeted molecular tests.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    59000Amniocentesis, therapeutic or diagnostic (not including ultrasound guidance)Procedure to obtain amniotic fluid prior to laboratory chromosome analysis; performed by obstetric provider
    76813Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (<14 weeks 0 days), transvaginal or transabdominalUltrasound commonly performed for guidance or pre‑procedural evaluation when performing amniocentesis (gestational age and fetal viability)
    88270Chromosome analysis, siblings or family member; may include amniotic fluid culture interpretationPerformed when parental or family member chromosome analysis is required for interpretation of fetal karyotype or suspected familial rearrangement
    88291Chromosome analysis using tissue other than blood or amniotic fluid, with banding and karyotypeAlternative cytogenetic analysis code used for other specimen types when additional tissue sources are needed
    81406Molecular cytogenetics (e.g., microarray), constitutional (eg, genomic microarray)Often ordered adjunctively or following abnormal karyotype for higher‑resolution detection of copy number variants

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    95Modifier 95 indicates that a service was provided via synchronous, real‑time audio‑video telehealth rather than in‑person. Per CMS, AAPC and professional associations, append modifier 95 to claim…- Use modifier 95 to indicate a service was furnished via synchronous, real‑time audiovisual telehealth (a live audio‑video conference between patient and provider) rather than in‑person. - Pair…
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    208U00000X
    207L00000X
    208100000X
    207R00000X
    163WF0300X
    261QH0100X
    2085N0700X
    342000000X

    Related ICD-10-CM Codes

    23 rows

    ICD-10-CM CodeDescription
    N94.89Other specified conditions associated with female genital organs and menstrual cycle
    N97.0Female infertility associated with anovulation
    O28.3Abnormal ultrasonic finding on antenatal screening of mother
    O28.4Abnormal radiological finding on antenatal screening of mother
    O35.2XX0Maternal care for (suspected) hereditary disease in fetus, not applicable or unspecified
    O35.2XX1Maternal care for (suspected) hereditary disease in fetus, fetus 1
    O36.4XX0Maternal care for intrauterine death, not applicable or unspecified
    O36.4XX1Maternal care for intrauterine death, fetus 1
    Q90.9Down syndrome, unspecified
    Q92.9Trisomy and partial trisomy of autosomes, unspecified

    Showing 1–10 of 23

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-88230-LYMPHOCYTE-TISSUE-CULTURE-NONNEOPLASTIC-DISORDER

    CPT 88230: Lymphocyte Culture for Nonneoplastic Disorder

    CPT-88233-TISSUE-CULTURE-SKIN-SOLID-TISSUE-NONNEOPLASTIC

    CPT 88233: Tissue Culture for Nonneoplastic Disorders

    CPT-88235-AMNIOTIC-FLUID-CHORIONIC-VILLUS-TISSUE-CULTURE

    CPT 88235: Tissue Culture Preparation from Amniotic Fluid or Chorionic Villi

    CPT-88237-BONE-MARROW-BLOOD-CELL-CULTURE-NEOPLASTIC-DISORDER

    CPT 88237: Cell Culture for Neoplastic Disorders

    CPT-88239-SOLID-TUMOR-CELL-CULTURE-NEOPLASTIC-DISORDER

    CPT 88239: Cell Culture From Solid Tumor for Neoplastic Disorder

    CPT-88240-CELL-LINE-CRYOPRESERVATION-STORAGE

    CPT 88240: Cryopreservation and Storage of Cell Line

    CPT-88241-THAW-AND-EXPAND-FROZEN-CELLS-SINGLE-ALIQUOT

    CPT 88241: Thaw and Expand Previously Frozen Cells, Single Aliquot

    CPT-88245-CHROMOSOME-ANALYSIS-SISTER-CHROMATID-EXCHANGE-SCE

    CPT 88245: Chromosome Analysis for Sister Chromatid Exchange

    CPT-88248-CHROMOSOME-ANALYSIS-BREAKAGE-SYNDROME

    CPT 88248: Chromosome Analysis for Breakage Syndromes

    CPT-88249-CHROMOSOME-ANALYSIS-BREAKAGE-SYNDROME-CLASTOGEN-STRESS

    CPT 88249: Chromosome Analysis for Breakage Syndrome, 100-Cell Clastogen Test

    Showing 1–10 of 26

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.